47M.BE - MedMira Inc

Berlin - Berlin Delayed Price. Currency in EUR
+0.0040 (+6.25%)
At close: 09:46PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close0.0640
Bid0.0530 x 5882400
Ask0.0830 x 3000000
Day's Range0.0610 - 0.0680
52 Week Range0.0365 - 0.1150
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateJun 27, 2023 - Jul 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for 47M.BE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Simply Wall St.

      MedMira Second Quarter 2023 Earnings: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2022)

      MedMira ( CVE:MIR ) Second Quarter 2023 Results Key Financial Results Revenue: CA$170.5k (down 43% from 2Q 2022). Net...


      MedMira Reports Second Quarter Results FY2023

      MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2023.


      Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada

      Today, MedMira Inc. (MedMira) (TSXV:MIR) provides an update on its progress to achieve regulatory approval in Canada for its Reveal® TP (Syphilis) antibody test.

    • Business Wire

      Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis

      PROVIDENCE, R.I. & HALIFAX, Nova Scotia, February 20, 2023--Maternova gains distribution rights across the U.S. and Latin America for MedMira’s rapid diagnostics for sexually transmitted diseases.


      MedMira Enters into Partnership with Maternova for USA and Latin America

      Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the singing of a multinational distribution agreement with ​Maternova, Inc., Rhode Island, USA.


      MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

      Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of the CE mark for its VYRA™ CoV2Flu Antigen Test (VYRA™ CoV2Flu), the fastest combination antigen test available to detect SARS-CoV-2, Flu A and Flu B.


      Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)

      Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection - (available: https://www.mdpi.com/2076-0817/12/1/77), in the special edition of Pathogens by MDPI, a Swiss based medical journal.


      MedMira Reports First Quarter Results FY2023

      MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2022.


      MedMira Introduces VYRA TriDemic

      Today, MedMira Inc. (MedMira) (TSXV:MIR) presents its latest addition to the VYRATM product line, the VYRATM TriDemic Antigen Rapid Test for the simultaneous detection of SARS-CoV-2, Flu A, Flu B and Respiratory Syncytial Virus (RSV).


      MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

      MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2022.


      MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

      October 14, 2022 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test (VYRA™ COVID-19), the fastest SARS-CoV-2 Antigen test available.

    • News Direct

      MedMira provides Progress Update

      Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific & Regulatory Affairs and provides an update on its regulatory progress in t...

    • GlobeNewswire

      MedMira Strengthens and Expands Board

      HALIFAX, Nova Scotia, July 14, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Ms. Pascale Nini to the Board of Directors. In addition, Mr. Thomas Bergmann was appointed as the Company’s independent Chairman. The new Board structure and the appointment of the new independent director will provide further strength to the Company’s growth plans. “We are delighted to bring Ms. Nini to the board and gain access to her experience, network and expertise

    • GlobeNewswire

      MedMira Reports Third Quarter Results FY2022

      HALIFAX, Nova Scotia, June 29, 2022 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2022. Profit and Loss Highlights Revenue: The Company recorded revenues in Q3 FY2022 of $323,925 compared to $64,631 for the same period last year. The increase in revenue in comparison with Q3 FY2021 was due to higher sales in for its Miriad®, Multiplo® and Reveal® product lines.Gross Profit: The Company recorded a gross profit in Q3

    • GlobeNewswire

      MedMira Receives Patent for its Unique Quantitative Diagnostic System

      HALIFAX, Nova Scotia, June 06, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system. Through this new patent, MedMira is to further diversify its patent portfolio and expand on its Rapid Vertical Flow Technology® (RVF) based diagnostic tests. This is a step forward in empowering the Company’s strategic vision by offering a rapid multiplexed quantitative diagnostic system